MedPath

The Trio Laser Module for Hair Removal Treatment

Not Applicable
Completed
Conditions
Hair Removal Treatment
Interventions
Device: Hair removal treatment
Registration Number
NCT04599751
Lead Sponsor
Alma Lasers
Brief Summary

The study is aimed to assess the safety and efficacy of hair removal treatments, using the Trio Laser Module (Alma Lasers).

The study will include 36 subjects that will undergo axilla and bikini line hair removal treatments. Safety and efficacy will be evaluated 3- months after the last treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
37
Inclusion Criteria
  • Willing to undergo hair removal treatments at the Axilla and the Bikini line.
  • Between 18 and 70 years of age.
  • Reasonably good health, as defined by the Investigator.
  • Agrees to avoid tanning during their participation in this study.
  • Agrees to shave the treatment area prior to the treatment visit, according to the investigator's instructions.
  • Subjects with dark brown hair.
  • Eligible for treatment following a test spot without negative effects.
  • Provided written Informed Consent and photo consent.
Exclusion Criteria
  • History of laser hair removal in the treatment area.
  • Pregnant, lactating or planning to get pregnant within the study period.
  • Unwilling to use a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, if of childbearing age.
  • History of photosensitivity or use of medication with photosensitizing properties.
  • Active infection in the treatment area.
  • History or evidence of any chronic or reoccurring skin disease or disorder affecting the treatment area.
  • History of keloid scarring or hypertrophic scar formation.
  • Tattoo in the treatment area.
  • Subject has been tanning within the past 30 days.
  • History of confounding cancerous or pre-cancerous skin lesions in the treatment area.
  • History of connective, metabolic or atrophic skin disease.
  • Subject has used prohibited therapies, oral prescription medication, or topical meds (steroids) on the treatment area within 30 days prior to enrollment.
  • History of autoimmune disorder

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Hair removal treatmentHair removal treatmentTrio laser module (Alma Lasers)
Primary Outcome Measures
NameTimeMethod
Safety- Adverse eventsThrough study completion, an average of 1 year

Adverse events and serious AE reported at any time during the trial or follow-up

Change in hair count3 month after the last treatment

Change in hair count, preformed by blinded evaluators, based on photographs taken at 3m FU visit compared to baseline

Secondary Outcome Measures
NameTimeMethod
Investigator's assessment of the tolerability to the treatment using a 5-point Likert scale (when "0" indicates "none" and "4" indicates "sever").up to 24 weeks

The investigator will assess the treatment area and score treatment related side effects using a 5-point likert scale, before and after the treatment

Subject treatment related pain assessment, using VAS ( when "0" indicates "no pain" and "10" " worst possible pain"up to 24 weeks

Subjects will be requested to scale their treatment related pain

Subject's tolerability to the treatment, using a 5-point Likert scale (when "0" indicates "none" and "4" indicates "sever").up to 24 weeks

Subjects will be requested to scale any sensation of stinging, tingling, itching and, burning using the 5-point Likert scale, before and after the treatment

Subject's satisfaction from the treatment, using a 5-point Likert scale (when "1" indicates very dissatisfied and "5" very satisfied)3 months after the last treatment

Subjects will be requested to scale their satisfaction from the treatment

Trial Locations

Locations (2)

Skin Care Research, LLC

🇺🇸

Hollywood, Florida, United States

Tennessee Clinical Research Center

🇺🇸

Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath